Immunovant, Inc.
IMVT • NASDAQ
Immunovant, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Eric Venker, with a market cap of $4.9B.
CEOEric Venker
Next Earnings
Upcoming earnings announcement for Immunovant, Inc.
Date
Thursday, May 28, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q4 2026
EPS Estimate
-$0.58
Earnings History
Past 12 earnings reports for Immunovant, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Q3 2026 | -$0.61Est: -$0.71 | +14.1% | -Est: $2.4M | -100.0% |  10-Q |
| Nov 10, 2025 | Q2 2026 | -$0.73Est: -$0.72 | -1.4% | - | — | 10-Q |
| Aug 11, 2025 | Q1 2026 | -$0.71Est: -$0.68 | -4.4% | - | — | 10-Q |
| May 29, 2025 | Q4 2025 | -$0.64Est: -$0.72 | +11.1% | - | — | 10-K |
| Feb 6, 2025 | Q3 2025 | -$0.76Est: -$0.76 | 0.0% | - | — | 10-Q |
| Nov 7, 2024 | Q2 2025 | -$0.74Est: -$0.60 | -23.3% | - | — | 10-Q |
| Aug 6, 2024 | Q1 2025 | -$0.60Est: -$0.53 | -13.2% | - | — | 10-Q |
| May 29, 2024 | Q4 2024 | -$0.52Est: -$0.43 | -20.9% | - | — | 10-K |
| Feb 12, 2024 | Q3 2024 | -$0.36Est: -$0.43 | +16.3% | - | — | 10-Q |
| Nov 9, 2023 | Q2 2024 | -$0.45Est: -$0.48 | +6.2% | - | — | — |
| Aug 10, 2023 | Q1 2024 | -$0.57Est: -$0.45 | -26.7% | - | — | 10-Q |
| May 22, 2023 | Q4 2023 | -$0.46Est: -$0.43 | -7.0% | - | — | — |